Pelthos Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Pelthos Therapeutics Inc. (PTHS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Pelthos Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.76M, a 600.51% increase year-over-year.
- Pelthos Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.24M, a 206.93% increase year-over-year.
- Pelthos Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.00M, a 406.58% increase year-over-year.
- Pelthos Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $394.00K, a 7.65% increase year-over-year.
- Pelthos Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $3.95M, a 171.75% increase from fiscal 2024.
- Pelthos Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.46M, a 16.05% decline from fiscal 2023.
- Pelthos Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.73M, a 1473.58% increase from fiscal 2022.
- Pelthos Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $110.15K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.76M 10-Q · filed 2026-08-13 | $4.00M derived: sum of 2 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.24M 10-Q/A · filed 2026-08-13 | |||||
| 2025-12-31 | $3.95M 10-K · filed 2026-03-19 | |||||
| 2025-09-30 | $2.00M 10-Q · filed 2025-11-13 | $2.40M derived: sum of 2 quarters · filed 2026-08-13 | $2.80M derived: sum of 3 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $394.00K 10-Q · filed 2026-08-13 | $341.58K 10-Q · filed 2025-08-13 | $798.00K derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $404.00K 10-Q/A · filed 2026-08-13 | $403.92K 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $1.46M 10-K · filed 2026-03-19 | $1.46M 10-K · filed 2025-03-27 | ||||
| 2024-09-30 | $395.00K 10-Q · filed 2025-11-13 | $395.42K 10-Q · filed 2024-11-13 | $761.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.05M derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $366.00K 10-Q · filed 2025-11-13 | $366.50K 10-Q · filed 2024-08-13 | $659.00K derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2024-03-31 | $293.00K 10-Q · filed 2025-11-13 | $292.55K 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | $1.73M 10-K · filed 2025-03-27 | |||||
| 2023-09-30 | $342.43K 10-Q · filed 2024-11-13 | $669.77K derived: sum of 2 quarters · filed 2024-11-13 | $941.99K derived: sum of 3 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $327.34K 10-Q · filed 2024-11-13 | $599.56K derived: sum of 2 quarters · filed 2024-11-13 | ||||
| 2023-03-31 | $272.22K 10-Q · filed 2024-11-13 | |||||
| 2022-12-31 | $110.15K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |